FLT3 and myelodysplastic syndrome: In this phase II study, older patients (≥ 66 years) with AML or higher-risk MDS (IPSS-R > 4.5), including both wild type and mutated FLT3 disease, considered not suitable for intensive cytotoxic treatment, were randomized between 10-day decitabine with or without midostaurin.